Skip to main content
Equibles

ANTIPODES PARTNERS Ltd

Position in VRTX — Vertex Pharmaceuticals Inc / Ma

CIK 1652442 ROYAL EXCHANGE, C3
Back to VRTX Full portfolio

Position in VRTX

as of Jun 30, 2026 · filed Aug 6, 2026
Position Value
$116,731
+$60,021 QoQ
Shares Held
235
+85.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,474
of 1,745 holders
Holding Since
Dec 2023
9 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in VRTX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ANTIPODES PARTNERS Ltd holds $60,434,232 across 11 Biotechnology names. VRTX ranks #6 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ALNY
Alnylam Pharmaceuticals, Inc.
 163,533 $49,228,338
2 HUMA
Humacyte, Inc.
 10,103,647 $7,880,844
3 GPCR
Structure Therapeutics Inc.
 51,262 $2,751,231
4 ARGX
Argenx SE
 187 $173,492
5 IMNM
Immunome Inc.
 7,971 $168,905
6 VRTX
Vertex Pharmaceuticals Inc / Ma
This page 		235 $116,731
7 DNTH
Dianthus Therapeutics, Inc. /DE/
 379 $36,944
8 TNGX
Tango Therapeutics, Inc.
 1,037 $32,416

All Filings in VRTX

Export CSV
9 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $116,731 235
2026-03-31 $56,710 127
2025-12-31 $57,576 127
2025-06-30 $107,293 241
2025-03-31 $123,629 255
2024-09-30 $59,461,873 127,853
2024-06-30 $59,665,712 127,295
2024-03-31 $79,171,093 189,400
2023-12-31 $36,180,658 88,920